has said hes a big fan of peptides and has used them himself
GLP-1 receptor activation contributes glucose-dependent insulin secretion and central appetite suppression
The dose per day or per session
Track simple signals of benefit: fewer snacks, smaller portions, consistent bowel habits, and a small downward trend on the scale over 8-12 weeks
Abutment keratosis is due to abnormalities keratinization of the lining of the upper part of the hair follicle (the follicular infundibulum) The scale fills the follicle instead of exfoliating
Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
